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Abstract
In colorectal cancer (CRC), an inherited susceptibility risk affects about 35% of patients, whereas high-penetrance germline
mutations account for ,6% of cases. A considerable proportion of sporadic tumors could be explained by the coinheritance
of multiple low-penetrance variants, some of which are common. We assessed the susceptibility to CRC conferred by
genetic variants at the TGFBR1 locus. We analyzed 14 polymorphisms and the allele-specific expression (ASE) of TGFBR1 in
1025 individuals from the Spanish population. A case-control study was undertaken with 504 controls and 521 patients with
sporadic CRC. Fourteen polymorphisms located at the TGFBR1 locus were genotyped with the iPLEX Gold (MassARRAY-
Sequenom) technology. Descriptive analyses of the polymorphisms and haplotypes and association studies were performed
with the SNPator workpackage. No relevant associations were detected between individual polymorphisms or haplotypes
and the risk of CRC. The TGFBR1*9A/6A polymorphism was used for the ASE analysis. Heterozygous individuals were
analyzed for ASE by fragment analysis using cDNA from normal tissue. The relative level of allelic expression was
extrapolated from a standard curve. The cutoff value was calculated with Youden’s index. ASE was found in 25.4% of
patients and 16.4% of controls. Considering both bimodal and continuous types of distribution, no significant differences
between the ASE values of patients and controls were identified. Interestingly, a combined analysis of the polymorphisms
and ASE for the association with CRC occurrence revealed that ASE-positive individuals carrying one of the most common
haplotypes (H2: 20.7%) showed remarkable susceptibility to CRC (RR: 5.25; 95% CI: 2.547–5.250; p,0.001) with a synergy
factor of 3.7. In our study, 54.1% of sporadic CRC cases were attributable to the coinheritance of the H2 haplotype and
TGFBR1 ASE. These results support the hypothesis that the allelic architecture of cancer genes, rather than individual
polymorphisms, more accurately defines the CRC risk.
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Introduction
Colorectal cancer (CRC) affects more than one million people
worldwide every year and is becoming the most prevalent type of
cancer in developed countries [1]. The underlying causes of CRC
are combinations of environmental and genetic factors in different
proportions. A considerable percentage of sporadic tumors could
be explained by the coinheritance of multiple low-penetrance
variants, some of which are common. Inherited susceptibility
underlies ,35% of the variance in CRC risk, whereas high-
penetrance germline mutations account for ,6% of cases [2].
Common genetic variants at several loci involved in the
transforming growth factor beta (TGF-beta) superfamily signaling
pathway have been identified as low-penetrance variants that
affect CRC development, when an unbiased approach is used,
such as a genome-wide association (GWA) analysis [2].
TGF-beta is one of the most potent inhibitors of the
proliferation of epithelial cells. Abnormalities in this signaling
pathway are almost universal in cancer cells and are mediated
through a variety of mechanisms [3]. The TGF-beta receptor type
I (encoded by the TGFBR1 gene) is a mediator of TGF-beta
growth-inhibitory signals and has been targeted in several studies
of cancer susceptibility and progression, with frequently discordant
results [4–7].
Recently, a phenomenon called ‘‘allele-specific expression’’ (ASE)
was described; ASE occurs in the germline at the TGFBR1 gene in
10%–20% of CRC patients and generates an increased risk of CRC
(odds ratio [OR]: 8.7; 95% confidence interval [CI]: 2.6–29.1),
although the underlying genetic cause of this transcriptional variation
remains unknown [8]. More recently, contrary results were reported,
in that the ASE of TGFBR1 was observed as a rare event and no
increased susceptibility to CRC could be detected [9–14].
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30812
It is currently accepted that there is a direct association between
a genetic susceptibility to cancer and the number of risk alleles
carried by an individual [15]. Evidence for this assumption comes
from several studies in which the authors analyzed a combination
of a small number of susceptibility alleles at different loci [2]. The
2% of the population with the highest risk, who carried multiple
low-risk alleles, had an increase in CRC of about fourfold com-
pared with individuals with a median population risk [15].
In the present study, we aimed to map the genetic susceptibility
interactions for CRC at the TGFBR1 locus. Our results show that
individuals carrying the combination of a specific haplotype and
ASE have a substantially increased risk of CRC (relative risk [RR]:
5.25; 95% CI: 2.547–5.250; p,0.001), although neither of these
factors had a significant effect on CRC susceptibility when ana-
lyzed individually.
Methods
Objectives
The working hypothesis we tested in this study was that the
detailed intralocus allele architecture of TGFBR1 more precisely
predicts genetic susceptibility to CRC than do individual single-
nucleotide polymorphisms (SNPs). We aimed to map the genetic
susceptibility interactions at the TGFBR1 locus that affect CRC,
defined by 14 polymorphisms and TGFBR1 ASE, in a case-control
study.
Participants
Patients with sporadic CRC. Individuals with sporadic
CRC (n= 521) who underwent surgery with curative intention
were included in this study. Patients with familial adenomatous
polyposis or Lynch syndrome were excluded. Patients suspected of
having Lynch syndrome (tumors diagnosed earlier than 50 years of
age, with microsatellite instability) were also excluded. The median
age of the included patients at diagnosis was 67 years (range 23–93
years). The clinical and pathological characteristics of the CRC
patients are given in detail in Table 1.
Patients’ biological samples and clinical and pathological
information were obtained from the Biobanks at Elche University
Hospital and Castellon Provincial Hospital (Spain).
Controls. Controls (n= 504) with no personal history of cancer
and with diagnoses thought to be unrelated to the disease of interest
(e.g., bone fractures, multiple trauma, blood glucose irregularities,
vascular and heart diseases, complications associated with renal
failure) were selected from the Elche University Hospital Biobank
(Spain). Their median age was 72 years (range 23–98 years).
Description of procedures and investigations undertaken
DNA/RNA extraction and cDNA synthesis. DNA and
RNA were extracted from the peripheral blood leukocytes of the
controls and from the normal-appearing colonic mucosa of the
CRC patients. DNA/RNA extraction and cDNA synthesis were
performed as described previously [16].
Polymorphism selection. The selection of SNPs was based
on their association with the occurrence of TGFBR1 ASE, as
described by Valle et al. [8]. A total of 14 polymorphisms extending
along 71 kb at the TGFBR1 locus were genotyped. Six SNPs were
intragenic, five were located upstream from the gene, and three were
located downstream from the gene (Figure S1). The SNPs rs7034716
and rs6478974 are described as tagSNPs in this region, according to
the HapMap database (Data Rel27 Phase II+III).
SNP genotyping. MassARRAY Designer software (Seque-
nom) was used to design the PCR assay and iPLEX single-base
extension primers for the multiplexed analysis. iPLEX Gold assay
MassARRAY (Sequenom) is a primer extension process designed
to detect sequence differences at the single-nucleotide level. Allele-
specific differences in mass between extension products are
detected by MALDI-TOF/MS.
Analysis of the TGFBR1 9A/6A polymorphism. We have
previously reported the genotyping of the polymorphic repetitive
trinucleotide 9A/6A in TGFBR1 exon 1 (rs11466445) in patients
with sporadic CRC and in controls [16].
ASE analysis. We used cDNA from all the heterozygous 9A/
6A individuals to analyze the ASE of TGFBR1. To quantify the
ASE, we used a nine-point standard curve constructed with
dilutions of cDNAs from 9A and 6A homozygous individuals
dilutions: 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, and 1:9). A standard
curve (Pearson’s correlation coefficient .0.98) was used to inter-
polate the relative ASE for each individual. Each cDNA sample
was tested in triplicate. cDNA samples from three heterozygous
individuals were also used as calibrators throughout all the
quantitative ASE experiments to evaluate and correct for potential
interexperimental variation. The cutoff value was calculated with a
receiver operating curve analysis, to estimate the sensitivity and
specificity of the various cutoff points, and to select the best value
for Youden’s index.
Ethics
Written informed consent for inclusion in the respective
Biobank was obtained from every participating individual. The
study was approved by the ethics committees of the Elche and
Castellon Hospitals.
Statistical methods
Descriptive analyses of the polymorphisms and haplotypes were
performed with the genetic statistical platform SNPator [17].
Before the individual polymorphisms were analyzed, Hardy-
Weinberg equilibrium was confirmed for the control group. The
SNPator platform uses the PHASE program for haplotype
estimation. This program implements a Bayesian statistical
Table 1. Clinical and pathological characteristics of CRC
patients.
Variables Frequencies
Sex
Men 290 55.66%
Women 231 44.34%
Age
Median 67
Range 23–93
Location
Proximal 98 24.08%
Distal 309 75.92%
UK 114
Stage
I 8 2.74%
II 133 45.55%
III 146 50.00%
IV 5 1.71%
UK 229
(UK: unknown).
doi:10.1371/journal.pone.0030812.t001
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method for reconstructing haplotypes from population genotype
data.
Multivariate unconditional logistic regression models assuming
dominant, recessive, additive, or codominant modes of inheritance
were used to assess the associations between the polymorphisms or
haplotypes and CRC.
We explored the potential effects of modification by sex, age
(below vs over the median age: 67 years), tumor location (proximal
vs distal), and tumor stage (I and II vs III and IV) in the
corresponding stratified analysis.
A x2 test was used to evaluate the differences in variant carrier
frequencies between the patients group and the control group and
to analyze any association between the SNPs and the clinical and
pathological factors. Armitage’s trend test was used to calculate p
for trends in the additive model of inheritance. All p values were
two-sided and p,0.05 was considered significant. The results are
expressed as ORs and 95% CIs. Power was determined using
online statistical software (http://www.stat.ubc.ca/,rollin/stats/
ssize/caco.html). Bonferroni’s method to correct for multiple tests
was included in the analysis to ensure that the overall confidence
coefficient was maintained. A nonparametric Mann-Whitney U
test was used for the ASE analysis when the distribution was
considered continuous. The RR, synergy factor, and population
attributable risk percent (PAR%) were calculated in the combined
analysis of haplotypes and ASE.
Results
There was no statistically significant difference in the mean age
or sex distribution of the patients and controls
TGFBR1 polymorphisms and CRC
A total of 782 individuals (405 patients and 377 controls) were
genotyped for the 13 SNPs. The amount and/or quality of the
DNA of the remaining individuals were inadequate for analysis
with the iPlex technology. Quality control for genotyping was
assessed by real-time PCR with TaqMan probes for allelic dis-
crimination in 0.7% of the genotypes identified by iPLEX tech-
nology. Genotyping of the polymorphic repetitive trinucleotide
9A/6A in TGFBR1 exon 1 (rs11466445) was assessed in all pa-
tients and controls included in the study.
The allelic and genotype frequencies are shown in Tables S1
and S2, respectively. All the polymorphisms included in this study
had a minor allele frequency (MAF) higher than 8% (Tables S1
and S2). The genotype distribution in the control population did
not deviate significantly from that expected for a population in
Hardy–Weinberg equilibrium (P.0.25). The allelic frequencies
found were similar to those reported in the HapMap database
(http://hapmap.org) and the NCBI dbSNP (http://www.ncbi.
nlm.nih.gov/snp/).
Association studies of individual SNPs with CRC occurrence
showed significant results for SNPs rs7034716, rs10739778, and
rs334365, with ORs of 1.36–1.42 (Table 2). A stratified analysis
showed a significant association between the minor allele and a CRC
diagnosis at a younger age (,67 years) for the SNPs rs7033283,
7034462, 7034867, 12686783, 11466445, and rs928180 (Table 3).
No other significant association was found when the analysis was
stratified by sex, tumor location, or stage.
A linkage disequilibrium (LD) study showed a generally high
level of linkage between the polymorphisms analyzed. The linkage
values for more than 80% of pairs of SNPs resulted in D9.0.8.
The identified tagSNPs for this region included the SNPs
rs7034462, rs7034867, and rs928180, all with MAF,10% (Table
S3).
A haplotype analysis showed the presence of 17 and 27 different
haplotypes in the controls and patients, respectively. Only six of
those haplotypes (H1, H2, H3, H4, H5, and H13) had a frequency
higher than 1% in the controls; these were selected for the
association studies. Descriptions of the haplotypes and their
frequencies are given in Tables S4 and S5, respectively.
Some significant associations between the haplotypes and CRC
were found in the stratified analysis. For individuals aged over 67
years, the H2 and H5 haplotypes were associated with an increase
and a reduction in CRC, respectively. Individuals aged below 67
years and carrying the H1 haplotype had a lower risk of CRC.
Finally, male individuals carrying the H4 haplotype had a lower
risk of CRC (Table 4).
TGFBR1 ASE
An ASE analysis was performed on the informative individuals
for the rs11466445 polymorphism: 9A/6A heterozygous individ-
uals (71 patients and 67 controls; n = 138). The relative TGFBR1
expression calculated from a standard curve was plotted (Figure 1).
The median ASE ratio was slightly higher for the CRC patients
than for the controls (0.89660.317 vs 0.86260.155, respectively).
For the analysis in which ASE was considered to have a bimodal
type of distribution, individuals were considered positive for the
Table 2. Significant associations between individual TGFBR1
polymorphisms and crude CRC occurrence.
Polymorphism
Genotype
frequencies OR 95% CI P
rs7034716
CT CC+TT
CRC 148 255 1.420 (1.06–1.90) 0.0174
C 164 199
rs10739778
AC AA+CC
CRC 170 235 1.360 (1.02–1.81) 0.033
C 184 187
rs334365
AG AA+GG
CRC 161 235 1.404 (1.05–1.87) 0.0209
C 176 183
(CRC: colorectal cancer; C: controls; OR: odds ratio; CI: confidence interval).
doi:10.1371/journal.pone.0030812.t002
Table 3. Significant associations between individual TGFBR1
polymorphisms and CRC stratified by age at diagnosis (,67
years).
Polymorphism MAF OR 95% CI P
rs7033283 A 0.523 (0.29–0.95) 0.0325
rs7034462 T 0.526 (0.29–0.96) 0.0340
rs7034867 A 0.560 (0.32–0.99) 0.0432
rs12686783 T 0.576 (0.32–1.05) 0.0375
rs11466445 *6A 0.520 (0.29–0.92) 0.0288
rs928180 G 0.439 (0.22–0.87) 0.0157
(MAF: minor allele frequency; OR: odds ratio; CI: confidence interval).
doi:10.1371/journal.pone.0030812.t003
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presence of ASE if they demonstrated an allelic expression ratio
,0.78 or .1.27. These cutoff values corresponded to 9A/6A
allele proportions of 44:56 and 56:44, respectively (sensitivity:
0.295; specificity: 0.836; Youden’s index: 0.131; Table S6). In the
positive patients, a consistent relative overexpression of the *6A
allele was observed (P=0.045).
Eighteen patients (25.4%) and 11 controls (16.4%) were positive
for ASE, showing no significant association with cancer risk (OR:
1.697; 95% CI: 0.74–3.87; P=0.213). In the stratified analysis of
CRC, ASE was more frequently found in individuals with early-
stage tumors (P=0.016; Table S7).
No significant association was found when ASE was considered
a continuous variable (P=0.179).
Table 4. Significant associations between TGFBR1 locus
haplotype and CRC stratified by age at diagnosis and sex.
CRC C OR 95% CI P
Age
.67 years
Haplotype H2 n = 183 n = 225
Carriers 73 64
Non carriers 110 161 1.669 (1.10–2.52) 0.015
(CRC: colorectal cancer; C: controls; OR: odds ratio; CI: confidence interval).
doi:10.1371/journal.pone.0030812.t004
Figure 1. Relative expression of the TGFBR1 rs11466445 allele calculated from a standard curve. The TGFBR1 allele ratios in patients with
sporadic CRC (panel A) and controls (panel B). The ASE-negative area is represented by the colored rectangle between the cutoff values (0.78 and
1.27). The mean and standard deviation are shown for each sample.
doi:10.1371/journal.pone.0030812.g001
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Combined analysis of TGFBR1 ASE and haplotypes
We found a highly significant association between the second
most common haplotype H2 (patients: 24.07%; controls: 20.72%),
ASE (patients: 25.4%; controls: 16.4%), and CRC occurrence.
Individuals carrying the H2 haplotype with ASE showed a high
risk of CRC (P,0.0001; Table 5). When H2 and ASE were
considered independent factors, the frequencies observed in the
patients differed significantly from the expected frequencies
(P=0.013), but did not do so in the controls (P.0.05; Table S8).
The RR values for ASE and the H2 haplotype were 1.24 (95%
CI: 0.86–1.68; P=0.213) and 1.123 (95% CI: 0.98–1.28;
P=0.095), respectively. As a consequence, the expected combined
RR for ASE and H2 was 1.42, whereas the observed RR was
5.250 (95% CI: 2.55–5.25; P,0.0001). The resulting synergy
factor was 3.7 and the population attributable risk was 54.1%
(Table 6).
Discussion
According to our results, the combined analysis of multiple
genetic factors associated with cancer susceptibility, with insub-
stantial individual weights, might reveal a more precise intralocus
allelic architecture than can individual analyses, and define specific
subgroups of individuals with important levels of risk for CRC.
In the current work, we have presented evidence that indi-
viduals carrying the specific TGFBR1 H2 haplotype and TGFBR1
ASE have a high relative risk of CRC (RR=5.250; 95% CI: 2.55–
5.25), whereas the individual risk associated with each of these
factors is negligible. A considerable synergistic relationship was
identified in the combined analysis, lending support to the hypo-
thesis that the allelic architecture of cancer genes might more
accurately define the cancer risk. The calculated PAR% was
54.1%, indicating that more than half the sporadic CRC in our
population was attributable to the combination of the H2 and ASE
genetic factors at the TGFBR1 locus. Further independent studies
with larger samples are required to confirm these results.
It is currently accepted that the effect of most common low-
penetrance alleles is essentially independent and the possession of
an increased number of risk alleles is associated with an increased
cancer risk, consistent with a polygenic model of disease
susceptibility [15].
Our results suggest that intralocus epistatic interactions between
common variants of CRC susceptibility factors might exist. Direct
experimental evidence of the existence of mechanisms for such
intralocus epistatic interactions has been reported previously [18].
Modest gene expression changes can have significant biological
consequences, as seen in APC gene, where 50% constitutional
reductions in the expression of one allele can lead to the
development of familial adenomatous polyposis [19].
ASE is a widespread phenomenon affecting the expression of
20% of human genes. The allelic differences are heritable in an
autosomal manner and are not imprinted [20,21]. Defining ASE
will help us to appreciate the extent of functionally important
regulatory variations and to focus on candidate haplotypes that are
associated with variably expressed alleles, allowing the detailed
molecular characterization of specific polymorphisms [20].
ASE represents the phenotypic effect of unknown genetic
variations, and may involve one or more local or distant factors,
which may act in cis or trans. Moreover, cumulative effects,
epistasis, genotype-environment interactions, and pleiotropy may
account for the complex genetic architecture underlying these
transcriptional variations [22]. Plausible heterogeneity in regula-
tory factors, differences in selected cohorts of CRC patients, and
differences in methodological approaches may be responsible for
the apparently incongruent results published for TGFBR1 ASE [8–
14].
ASE has been measured by several authors by calculating the
dosage ratio (cDNA/gDNA) [8,10–12]. However, it is recognized
that this methodology may entail occasional inherent problems
with quantitative genotyping [9]. We decided that ASE should be
assessed relative to the hypothetical 1:1 ratio of the allelic dose
rather than by comparing the cDNA and gDNA doses in a single
sample. The relative quantification of the expression of each allele
by extrapolation from a standard curve might offer more precise
results [9,23]. An additional possible confounding factor for ASE
assessment could be the RNA source used. Lymphoblastoid cell
lines have been used in many studies [9–11]. However, trans-
formed lymphoblasts may undergo changes in their mRNA levels
compared with the original peripheral blood lymphocyte sample
because of biological noise and in vitro artifacts (the levels of
Epstein–Barr virus used to transform the cells, ATP levels, etc.), or
even extreme clonal effects may compromise an ASE analysis. For
these reasons, the use of bulk nontransformed cells or ex vivo cells is
recommended for ASE assays [22]. All previously reported
TGFBR1 ASE studies used SNPs as genetic markers [8–14].
SNaPshot [8,9,11] and pyrosequencing [10,12–14] technologies
have been used to analyze SNPs, and have generated discrepan-
cies in published TGFBR1 ASE results. We selected an insertion/
deletion polymorphism (rs11466445) associated with the ASE
phenomenon [8] and studied it with capillary electrophoresis
fragment analysis, which is the most appropriate methodology for
the analysis of this type of polymorphism.
Table 5. Association between TGFBR1 H2 haplotype and
TGFBR1 ASE.
Haplotype H2 carriers CRC C OR: inf; 95% CI:(6.92-inf)
ASE positive 8 0 RR: 5.250; 95% CI:(2.547–5.250)
ASE negative 4 17 P,0.0001
(CRC: colorectal cancer; C: controls; RR: relative risk; CI: confidence interval).
doi:10.1371/journal.pone.0030812.t005
Table 6. Association between the TGFBR1 H2 haplotype,
TGFBR1 ASE, and CRC.
CRC C RR (95% CI) P
ASE
Carriers 18 11
Non carriers 54 56 1.264 (0.86–1.68) 0.213
H2
Carriers 173 139
Non carriers 232 238 1.123 (0.98–1.28) 0.095
Carriers of H2+ASE 8 0
Non carriers of H2+ASE 4 17 5.250 (2.55–5.25) ,0.0001
Expected RR 1.42
Synergy factor 3.7
PAR% 54.1%
(CRC: colorectal cancer; C: controls; ASE: allele-specific expression; RR: relative
risk; CI: confidence interval; PAR%: population attributable risk percent).
doi:10.1371/journal.pone.0030812.t006
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We are aware of the limitations of this study. The sample size
used in this study allowed us to detect susceptibility factors with a
minor allele frequency of 8% with RR$2 or #0.5, and with 80%
power for the crude associations of simple factors. Therefore, the
significant associations we found for the SNPs and haplotypes were
underpowered. Furthermore, the size of this study sample did not
allow us to detect the effects of rare alleles. However, our intention
was to analyze the effects of the combination of common genetic
factors. The sensitivity to detect genetic susceptibility is lower
when the population is stratified. Therefore, the risk detected in
the combined analysis of ASE and the H2 haplotype based on the
available sample size is clearly underpowered. The specificity and
sensitivity values for that association were 95% and 25%,
respectively.
The expected frequencies for H2/ASE, when they were
considered as independent factors, were significantly different
from the observed frequencies in the patients (P=0.013) but not in
the controls (P.0.05; Table S8), suggesting that this combination
of factors may have a deleterious effect.
The presence of a haplotype associated with ASE suggests a cis
regulatory mechanism underlying ASE. Polymorphisms in the
gene promoter, enhancer, transcription-factor-binding sites, splic-
ing sites, RNA stability elements, or antisense RNAs might be
involved in the underlying mechanistic dysfunction [24].
Epistatic interactions are difficult to detect unless their marginal
effects are significant. There is also a statistical penalty conferred by
large-scale multiple testing, which may make the identification of
such interactions highly problematic. Therefore, further investiga-
tions using larger samples are required to ensure conclusive results.
The polymorphisms selected for studies of multifactorial genetic
associations with diseases, such as the present one, are of critical
importance. The high level of LD shown by the set of polymorphisms
used in this work allowed us to dissect the polymorphisms that
defined those subhaplotypes that are more strongly associated with
the disease. A submaximal LD effect may hide potentially useful
information that would be missed in those genetic epidemiology
studies in which predefined tagSNPs are used. At this point, it is
important to note that patterns of LD can differ markedly between
populations [25].
All common SNPs identified to date with GWA scans confer
modest cancer risks and the majority of susceptibility alleles have
ORs of,1.5. Furthermore, in the reported GWA studies, only 12%
of SNPs with MAFs of 5%–10% were tagged, indicating that these
strategies are not optimally configured to identify low-frequency
variants in this range of MAFs, some of which may have stronger
effects [2]. Fifty percent of the TGFBR1 intralocus polymorphisms
(7/14) used in the present study had MAFs ranging from 8% to
10%, allowing the detection of new risk factors.
Haplotype-based approaches may have greater power than
single-locus analyses when the SNPs are in strong LD with the risk
locus. New data-mining approaches are being used to overcome
potential complexities that arise in genetic studies from large
numbers of haplotypes, offering more insight into the genetic risk
factors associated with complex diseases [26].
Despite the limitations described above, our results suggest the
importance of TGFBR1 in the genetic susceptibility to so-called
‘‘sporadic’’ CRC. These results also offer a proof of concept for the
existence of intralocus epistatic interactions between common
variants associated with CRC susceptibility. Therefore, a detailed
map of genetic interactions is required for more accurate risk
assessment, which should allow cancer prevention strategies to be
targeted, and increasingly influence cancer treatments.
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